[go: up one dir, main page]

AU2003255969A1 - Use of cpg nucleic acids in prion-disease - Google Patents

Use of cpg nucleic acids in prion-disease

Info

Publication number
AU2003255969A1
AU2003255969A1 AU2003255969A AU2003255969A AU2003255969A1 AU 2003255969 A1 AU2003255969 A1 AU 2003255969A1 AU 2003255969 A AU2003255969 A AU 2003255969A AU 2003255969 A AU2003255969 A AU 2003255969A AU 2003255969 A1 AU2003255969 A1 AU 2003255969A1
Authority
AU
Australia
Prior art keywords
prion
disease
nucleic acids
cpg nucleic
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003255969A
Other versions
AU2003255969A8 (en
Inventor
Hans Kretzschmar
Shneh Sethi
Hermann Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical GmbH
Original Assignee
Coley Pharmaceutical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical GmbH filed Critical Coley Pharmaceutical GmbH
Publication of AU2003255969A1 publication Critical patent/AU2003255969A1/en
Publication of AU2003255969A8 publication Critical patent/AU2003255969A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003255969A 2002-07-17 2003-07-17 Use of cpg nucleic acids in prion-disease Abandoned AU2003255969A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39643202P 2002-07-17 2002-07-17
US60/396,432 2002-07-17
PCT/IB2003/003727 WO2004007743A2 (en) 2002-07-17 2003-07-17 Use of cpg nucleic acids in prion-disease

Publications (2)

Publication Number Publication Date
AU2003255969A1 true AU2003255969A1 (en) 2004-02-02
AU2003255969A8 AU2003255969A8 (en) 2004-02-02

Family

ID=30116027

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003255969A Abandoned AU2003255969A1 (en) 2002-07-17 2003-07-17 Use of cpg nucleic acids in prion-disease

Country Status (2)

Country Link
AU (1) AU2003255969A1 (en)
WO (1) WO2004007743A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69932717T2 (en) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
KR100863630B1 (en) 1999-09-25 2008-10-15 유니버시티 오브 아이오와 리써치 파운데이션 Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
SI1296714T1 (en) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US6943240B2 (en) 2000-09-15 2005-09-13 Coley Pharmaceuticals Gmbh Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
WO2003015711A2 (en) 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity
ES2734652T3 (en) 2002-04-04 2019-12-11 Zoetis Belgium S A Immunostimulatory oligonucleotides containing G and U
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
BR0315810A (en) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5' cpg nucleic acids and methods of use
EP1663316A2 (en) 2003-09-25 2006-06-07 Coley Pharmaceutical Group, Inc. Nucleic acid lipophilic conjugates
GEP20094767B (en) 2003-10-30 2009-09-10 Coley Pharm Group Inc C-class oligonucleotide analogs with enhanced immunostimulatory potency
JP2008506789A (en) 2004-07-18 2008-03-06 シーエスエル、リミテッド Immunostimulatory complex and oligonucleotide formulation for inducing enhanced interferon-gamma response
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2007030581A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
WO2007030580A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
KR20080072934A (en) 2005-11-25 2008-08-07 콜리 파마슈티칼 게엠베하 Immunostimulatory oligoribonucleotides
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2009027105A2 (en) * 2007-08-31 2009-03-05 Neurimmune Therapeutics Ag Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2009105641A2 (en) * 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3468773B2 (en) * 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション Immunomodulatory oligonucleotide
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP2001513776A (en) * 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU2001229592A1 (en) * 2000-01-21 2001-07-31 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
GB0001704D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
EP1350262B8 (en) * 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
WO2003015711A2 (en) * 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity

Also Published As

Publication number Publication date
WO2004007743A2 (en) 2004-01-22
WO2004007743A3 (en) 2004-03-04
AU2003255969A8 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
AU2003255969A1 (en) Use of cpg nucleic acids in prion-disease
AU2003286535A1 (en) Methods of manipulating nucleic acids
EP1578954A4 (en) 5' cpg nucleic acids and methods of use
IL166376A0 (en) Immunostimulatory nucleic acids
AU2003228627A1 (en) Application of cantilevers in nucleic acid sequencing
AU2002332679A1 (en) Targeted nucleic acid constructs and uses related thereto
AU2002341002A1 (en) Use of phosphorothiolate polynucleotides in ligating nucleic acids
AU2003281867A1 (en) Antisense nucleic acids
AU2003277729A1 (en) Dna/rna transduction technology and its clinical and basic applications
AU2001295841A1 (en) Human dna sequences
AU2003252983A1 (en) Amplification of nucleic acids
AU2003235096A1 (en) Novel protein and dna thereof
AU2002254126A1 (en) Nucleic acids for transforming fish cells and methods for their use
AU2002368251A1 (en) Characterizing nucleic acid and amino acid sequences in silico
AU2003265635A1 (en) Nphp nucleic acids and proteins
AU2003270645A1 (en) Beta1,4-N-ACETYLGALACTOSAMINYLTRANSFERASES, NUCLEIC ACIDS AND METHODS OF USE THEREOF
HK1082683A (en) 5' cpg nucleic acids and methods of use
AU2003241762A1 (en) Dna shuflling
AU2003258658A1 (en) Improved dna and proteins
AU2003262080A1 (en) Novel protein and dna thereof
AU2003272339A1 (en) Virulence-associated nucleic acids and proteins and uses thereof
AU2002314927A1 (en) Nucleic acid regulatory sequences and uses therefor
AU2002329425A1 (en) Dna sequencer
AU2003211562A1 (en) Novel dna and use thereof
AU2003304707A1 (en) Novel nucleic acids and polypeptides

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase